Published in Lancet Infect Dis on May 11, 2011
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med (2013) 2.31
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis (2014) 1.86
Vaccine-induced myeloid cell population dampens protective immunity to SIV. J Clin Invest (2014) 1.64
Novel vaccine vectors for HIV-1. Nat Rev Microbiol (2014) 1.55
Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A (2012) 1.46
Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? PLoS Biol (2016) 1.43
Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proc Natl Acad Sci U S A (2014) 1.39
Past, present and future: 30 years of HIV research. Nat Rev Microbiol (2013) 1.19
Vaccines for the 21st century. EMBO Mol Med (2014) 1.17
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One (2012) 1.17
Immunology. Immune activation with HIV vaccines. Science (2014) 1.07
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates. Vaccines (Basel) (2014) 1.04
Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS (2013) 1.01
Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa. J Acquir Immune Defic Syndr (2011) 0.97
Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS (2013) 0.97
A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine (2012) 0.96
Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci U S A (2014) 0.95
New concepts in HIV-1 vaccine development. Curr Opin Immunol (2016) 0.94
Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials (2014) 0.93
The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol (2014) 0.92
Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92
Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. PLoS Pathog (2015) 0.91
Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis (2014) 0.91
Novel HIV vaccine strategies: overview and perspective. Ther Adv Vaccines (2013) 0.90
Measurements of immune responses for establishing correlates of vaccine protection against HIV. AIDS Res Hum Retroviruses (2011) 0.90
Microbicides for HIV prevention. Indian J Med Res (2011) 0.90
Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa? Vaccine (2013) 0.88
Systems-level analysis of innate immunity. Annu Rev Immunol (2014) 0.88
Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks. J Virol (2014) 0.87
HIV incidence and prevalence among cohorts of women with higher risk behaviour in Bloemfontein and Rustenburg, South Africa: a prospective study. BMJ Open (2012) 0.86
A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J Virol (2014) 0.86
Progress toward active or passive HIV-1 vaccination. J Exp Med (2016) 0.86
Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women. PLoS One (2012) 0.86
Application of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative Vaccines. J Immunol Res (2015) 0.84
Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials. PLoS One (2011) 0.84
Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. J Immunol (2014) 0.84
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. PLoS One (2015) 0.83
Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Proc Natl Acad Sci U S A (2014) 0.83
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. PLoS One (2015) 0.82
Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial. Clin Trials (2015) 0.82
Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239. J Virol (2014) 0.82
The Art of HIV Elimination: Past and Present Science. J AIDS Clin Res (2015) 0.82
Adolescent decision making about participation in a hypothetical HIV vaccine trial. Vaccine (2015) 0.82
Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen. Vaccine (2015) 0.82
Accelerating HIV-1 Vaccine Efficacy Trials. Cell (2014) 0.82
Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. Proc Natl Acad Sci U S A (2015) 0.82
Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy. Front Immunol (2014) 0.81
Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study. PLoS One (2015) 0.81
Challenges in the design of a T cell vaccine in the context of HIV-1 diversity. Viruses (2014) 0.81
An assessment of fishing communities around Lake Victoria, Uganda, as potential populations for future HIV vaccine efficacy studies: an observational cohort study. BMC Public Health (2014) 0.81
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev (2016) 0.80
HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. Curr HIV Res (2013) 0.80
First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis (2014) 0.80
New clinical trial designs for HIV vaccine evaluation. Curr Opin HIV AIDS (2013) 0.80
Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy. Virology (2015) 0.79
The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants. Int J STD AIDS (2013) 0.79
WHO guidance grounded in a comprehensive approach to sexual and reproductive health and human rights: topical pre-exposure prophylaxis. J Int AIDS Soc (2014) 0.79
The HVTN 503/Phambili study: efficacy is always the issue. Lancet Infect Dis (2011) 0.79
Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions. Hum Vaccin Immunother (2016) 0.79
Bone Marrow Gene Therapy for HIV/AIDS. Viruses (2015) 0.79
The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy. Gene Ther (2015) 0.79
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. J AIDS Clin Res (2015) 0.79
Lessons learned from HIV vaccine clinical efficacy trials. Curr HIV Res (2013) 0.79
Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol (2016) 0.79
Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques. PLoS One (2015) 0.78
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Vaccine (2014) 0.78
Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection. PLoS One (2016) 0.78
Regulation of SIV antigen-specific CD4+ T cellular immunity via autophagosome-mediated MHC II molecule-targeting antigen presentation in mice. PLoS One (2014) 0.78
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Curr Opin Virol (2016) 0.78
Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa. J Acquir Immune Defic Syndr (2014) 0.77
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol Ther Methods Clin Dev (2016) 0.77
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. PLoS One (2016) 0.77
Recent developments in clinical trial designs for HIV vaccine research. Hum Vaccin Immunother (2015) 0.77
Human parvovirus 4 'PARV4' remains elusive despite a decade of study. F1000Res (2017) 0.77
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. J Virol (2014) 0.77
Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. PLoS One (2014) 0.77
Current views on the potential for development of a HIV vaccine. Expert Opin Biol Ther (2017) 0.77
Role of HLA Adaptation in HIV Evolution. Front Immunol (2016) 0.76
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog (2017) 0.76
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS One (2016) 0.76
Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. PLoS One (2016) 0.76
Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev (2017) 0.76
Significant contribution of subtype G to HIV-1 genetic complexity in Nigeria identified by a newly developed subtyping assay specific for subtype G and CRF02_AG. Medicine (Baltimore) (2016) 0.76
Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. Immunol Rev (2017) 0.76
Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial. J Acquir Immune Defic Syndr (2016) 0.75
Causal analysis of ordinal treatments and binary outcomes under truncation by death. J R Stat Soc Series B Stat Methodol (2016) 0.75
HIV-1 prophylactic vaccines: state of the art. J Virus Erad (2016) 0.75
New prospects for a preventive HIV-1 vaccine. J Virus Erad (2015) 0.75
Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations. PLoS One (2017) 0.75
Recent Insights into the HIV/AIDS Pandemic. Microb Cell (2016) 0.75
A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines. Clin Med Insights Pathol (2017) 0.75
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. Front Immunol (2017) 0.75
Is the HIV vaccine our best shot? - Why the answer to HIV prevention will be found in South Africa. SACEMA Q (2015) 0.75
HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response. Expert Rev Vaccines (2016) 0.75
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49
Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Hormonal contraception and the risk of HIV acquisition. AIDS (2007) 5.05
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis (2008) 4.47
Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 3.74
Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med (2004) 3.52
Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol (1999) 3.22
Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr (2007) 3.03
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A (1997) 3.02
The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS (2001) 2.87
Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol (2004) 2.58
Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (2010) 2.20
Simultaneous inferences on the contrast of two hazard functions with censored observations. Biometrics (2002) 2.18
Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther (2004) 1.93
Synergistic copathogens--HIV-1 and HSV-2. N Engl J Med (2007) 1.70
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS (2010) 1.63
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immune Defic Syndr (2005) 1.51
Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis (2005) 1.41
Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. J Infect Dis (2011) 1.20
A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects. AIDS Res Hum Retroviruses (2006) 1.19
Uptake of male circumcision in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr (2009) 1.10
HIV type 1 subtype C gag and nef diversity in Southern Africa. AIDS Res Hum Retroviruses (2007) 1.05
HIV molecular epidemiology: transmission and adaptation to human populations. Curr Opin HIV AIDS (2009) 0.94
Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants. Vaccine (2009) 0.88
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (2005) 11.25
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis (2006) 9.25
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2002) 6.99
Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis (2005) 6.59
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med (2009) 5.78
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med (2009) 5.47
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods (2007) 4.69
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis (2007) 4.52
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA (2003) 4.38
Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science (2006) 4.35
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA (2008) 4.19
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 4.18
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07
Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis (2008) 4.05
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis (2007) 3.95
Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One (2008) 3.94
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis (2008) 3.92
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS (2009) 3.91
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med (2007) 3.66
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS (2007) 3.58
Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol (2004) 3.56
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One (2008) 3.40
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis (2006) 3.40
Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. J Clin Microbiol (2006) 3.37
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS (2013) 3.36
Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav (2009) 3.29
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis (2004) 3.23
Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis (2004) 3.23
Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis (2003) 3.19
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16
Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A (2003) 3.14
A population-based study of primary human herpesvirus 6 infection. N Engl J Med (2005) 3.07
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis (2004) 3.01
Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med (2005) 3.01
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood (2005) 2.97
Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS (2008) 2.96
Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS (2010) 2.90
Risk factors for herpes simplex virus transmission to pregnant women: a couples study. Am J Obstet Gynecol (2005) 2.89
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine (2006) 2.89
Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med (2007) 2.88
Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS (2009) 2.86
When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther (2006) 2.85
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol (2002) 2.83
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J (2013) 2.80
HIV-1-discordant couples in sub-Saharan Africa: explanations and implications for high rates of discordancy. Curr HIV Res (2007) 2.78
Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS (2004) 2.78
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis (2008) 2.77
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76
Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.72
Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol (2002) 2.71
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog (2009) 2.70
CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis (2006) 2.68
Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis (2002) 2.67
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol (2003) 2.64
Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis (2010) 2.62
Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog (2008) 2.59